Immix Biopharma(NASDAQ:IMMX) 
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and...
Website: https://www.immixbio.com
Founded: 2012
IPO Price: $5 (Dec 16, 2021)
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.58
H 1.64
L 1.50
C 1.50
V 33,513
10EMA 1.50
20EMA 1.50
60EMA 1.50
120EMA 1.50
250EMA 1.50